U.S. Dermatological Drugs Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. dermatological drugs market highlights
- The U.S. dermatological drugs market generated a revenue of USD 8,752.6 million in 2025 and is expected to reach USD 18,250.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 9.7% from 2026 to 2033.
- In terms of segment, psoriasis was the largest revenue generating indication in 2025.
- Psoriasis is the most lucrative indication segment registering the fastest growth during the forecast period.
Dermatological drugs market data book summary
| Market revenue in 2025 | USD 8,752.6 million |
| Market revenue in 2033 | USD 18,250.1 million |
| Growth rate | 9.7% (CAGR from 2026 to 2033) |
| Largest segment | Psoriasis |
| Fastest growing segment | Psoriasis |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Acne, Alopecia, Psoriasis, Rosacea |
| Key market players worldwide | AbbVie Inc, Pfizer Inc, GSK PLC ADR, Sun Pharmaceutical Industries, GALDERMA, Amgen Inc, Johnson & Johnson Services, Inc., Novartis AG ADR, Eli Lilly and Co, Almirall SA, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.4% of the global dermatological drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. dermatological drugs market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,399.2 million by 2033.
The U.S. dermatology drugs market is experiencing steady growth, fueled by increasing prevalence of chronic skin conditions such as psoriasis, acne, and atopic dermatitis. The rising incidence of these conditions, combined with greater public awareness of skin health, is driving demand for both prescription and over-the-counter dermatological treatments.
The U.S. market is also benefiting from advancements in drug technologies, particularly biologics and targeted therapies, which are significantly improving treatment outcomes for patients with complex and chronic skin disorders. These developments are expected to sustain market growth during the forecast period.
No credit card required*
Publish Date: Jul 02, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Dermatological Drugs Market Scope
Dermatological Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| GSK PLC ADR | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | www.sunpharma.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Almirall SA | View profile | 1,885 | Ronda General Mitre 151, Barcelona, Spain, 08022 | www.almirall.es |
| Bausch Health Companies Inc | View profile | 20,270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | www.bauschhealth.com |
| GALDERMA | View profile | - | - | - |
U.S. Dermatological Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Dermatological Drugs Market Outlook will help companies and investors design strategic landscapes.
Psoriasis was the largest segment with a revenue share of 38.68% in 2025.
Horizon Databook has segmented the U.S. dermatological drugs market based on acne, alopecia, psoriasis, rosacea covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. dermatology drugs market is experiencing steady growth, fueled by increasing prevalence of chronic skin conditions such as psoriasis, acne, and atopic dermatitis. The rising incidence of these conditions, combined with greater public awareness of skin health, is driving demand for both prescription and over-the-counter dermatological treatments.
The U.S. market is also benefiting from advancements in drug technologies, particularly biologics and targeted therapies, which are significantly improving treatment outcomes for patients with complex and chronic skin disorders. These developments are expected to sustain market growth during the forecast period.
- U.S. Dermatological Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Psoriasis
- Atopic Dermatitis (Eczema)
- Fungal infections
- Acne
- Alopecia
- Rosacea
- Others
- U.S. Dermatological Drugs Market Type Outlook (Revenue, USD Million , 2021-2033)
- Prescription
- Over-the-Counter (OTC)
- U.S. Dermatological Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical Administration
- Oral Administration
- Parenteral Administration
- U.S. Dermatological Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Corticosteroids
- Retinoids
- Antibiotics
- Antifungals
- Calcineurin Inhibitors
- Others
- U.S. Dermatological Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to Dermatological Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Dermatological Drugs Market Outlook databook
- Our clientele includes a mix of Dermatological Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Dermatological Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Dermatological Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Dermatological Drugs Market, 2021-2033 (US$M)
US Indication - Dermatological Drugs Market Statistics, 2025 - 2033 (US$M)
